- Home
- VTR vs TAK Comparison
VTR vs TAK Comparison
Compare VTR & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTR | TAK |
|---|---|---|
| Founded | 1983 | 1781 |
| Country | United States | Japan |
| Employees | N/A | 47455 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.0B | 52.4B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | VTR | TAK |
|---|---|---|
| Price | $93.76 | $16.97 |
| Analyst Decision | Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $87.62 | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 2.9M |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | 2.38% | ★ 3.24% |
| EPS Growth | ★ 184.21 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $5,833,980,000.00 | N/A |
| Revenue This Year | $14.00 | $0.16 |
| Revenue Next Year | $8.35 | $1.22 |
| P/E Ratio | $837.32 | ★ $41.25 |
| Revenue Growth | ★ 18.47 | N/A |
| 52 Week Low | $64.72 | $12.99 |
| 52 Week High | $93.05 | $18.90 |
Technical Indicators
Market Signals| Indicator | VTR | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 71.38 | 67.87 |
| Support Level | $84.56 | $15.88 |
| Resistance Level | N/A | $18.86 |
| Average True Range (ATR) | 1.96 | 0.23 |
| MACD | 1.04 | 0.18 |
| Stochastic Oscillator | 94.49 | 91.32 |
Price Performance
Historical ComparisonAbout VTR Ventas Inc.
Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.